![]() |
|
|
Vol. 26, Issue 5, 490-496, May 1998
Merck Frosst Centre for Therapeutic Research (J.M.S., P.E.M., S.H.D., B.P.K., P.P., J.A.Y., D.A.N.-G.), and Drug Metabolism Department, Merck Research (T.R.)
| |
Abstract |
|---|
|
|
|---|
Induction of cytochromes P450 (P450s) by drugs can lead to drug-drug interactions. Primary hepatocytes have been reported to retain inducible P450s. To optimize the use of primary hepatocytes for predicting induction of P450 (CYP 3A and 2B) expression in vivo, both culture conditions and expression of induction potentials were investigated. In rat hepatocytes, basal CYP 3A1/2 expression was better maintained in cells cultured on Matrigel compared with collagen when low concentrations of dexamethasone were used. However, CYP 3A1/2 induction was not affected by either matrix. In contrast, induction of CYP 2B1/2 by phenobarbital was markedly stronger in hepatocytes cultured on Matrigel. To further validate the in vitro model, Sprague-Dawley rats and isolated hepatocytes cultured on Matrigel were exposed to a series of compounds. In an attempt to minimize large variability between experiments, a novel approach for calculating induction potential was applied. In vitro results for CYP 3A1/2 and 2B1/2 induction correlated well with those observed in vivo. In contrast with rat hepatocytes, basal CYP 3A4 expression in human hepatocytes decreased rapidly in cells cultured on either Matrigel or collagen. However, CYP 3A4 inducibility was retained in cells cultured on either matrix. Interestingly, induction of CYP 3A4 in human hepatocytes by several model compounds did not correlate with the induction of CYP 3A1/2 in rat hepatocytes. This in vitro assay should facilitate the demand for a fast and reproducible method for addressing P450 induction by numerous compounds at the drug discovery stage.
| |
Introduction |
|---|
|
|
|---|
Cytochromes
P450 (P450s)2 form a gene
superfamily that are involved in the metabolism of a variety of
chemically diverse substances ranging from endogenous compounds to
xenobiotics including drugs, carcinogens, and environmental pollutants.
Although P450 regulation is still poorly understood, it is well known
that some of the P450 genes are induced severalfold by specific drugs.
This may cause variability in enzymatic activity with different groups of patients producing unexpected pharmacological activity of some drugs
as a result of drug-drug interactions (Wadhwa et al., 1987
). Knowledge of potential P450 inducibility by drug candidates, prior to
drug development, would greatly enhance the ability to develop drugs
that are free of P450-inducing properties. In the past, various animal
species have been used as models to investigate P450 induction by drug
candidates. The data obtained from such in vivo models has
proven to be beneficial in assessing P450 induction. However, at the
drug discovery stage this is difficult to carry out because of the
large numbers of animals and the large amount of compound needed to
conduct such experiments. In addition, there exist species differences
in P450 induction (Kocarek et al., 1994b
), making the
extrapolation from animals to humans unreliable. Therefore, having a
simple, robust, and reproducible in vitro model to study P450 induction would greatly facilitate the ability to develop drugs
devoid of these possible negative traits. Such a model would offer the
advantage of requiring less drug (<1 mg) and reducing the number of
animals used. In addition, confounding factors such as bioavailability,
blood, and liver levels of the drug would be avoided.
There are no known hepatoma cell lines able to express most of the
major forms of adult P450. Induction of P450s have been documented to
occur in primary cultured hepatocytes isolated from various species
including man (Combalbert et al., 1989
; Kocarek et
al., 1994b
; Schuetz et al., 1988
). However, it is well
known that primary cultured hepatocytes tend to lose expression of
specific liver functions, including P450s, as they adapt to culture
conditions over time (Schuetz et al., 1988
). In an attempt
to maintain the differentiated function of hepatocytes in culture, cell
culturists have tried various approaches, including manipulation of
culture medium with various hormonal supplementation (Decad et
al., 1977
; Jefferson et al., 1984
) and cocultures of
hepatocytes with other cells such as fibroblasts under the hypothesis
that factors produced by nonparenchymal cells may be important in
maintaining hepatocytes (Baffet et al., 1982
;
Guguen-Guillouzo et al., 1983
; Morin and Normand, 1986
).
Others have focused on the substratum to which hepatocytes attach
(Kleinman et al., 1985
). In this latter case, instead of
culturing hepatocytes on plastic dishes coated with a thin layer of
collagen, more complex matrices have been investigated including
fibronectin (Johansson and Hook, 1984
), extracts from rat liver (Reid
et al., 1980
), and more recently Matrigel (Li et
al., 1987
; Schuetz et al., 1988
). However, the best
culture conditions for maintaining constitutive and inducible P450
expression in primary hepatocytes remains unclear.
The objective of this study was to refine culture conditions and
validate the use of hepatocytes to study CYP 3A and 2B induction. Specifically, basal and inducible P450 expression were investigated in
rat (CYP 3A1/2 and 2B1/2) and human (CYP 3A4) hepatocytes cultured on
collagen or Matrigel. These two isozymes were targeted because in
humans, CYP 3A4 is the most abundant form of liver P450 and is
responsible for metabolism of >60% of all clinically used drugs (Cholerton et al., 1992
; Molowa et al., 1986
),
and CYP 2B1 has been associated with rodent tumorogenesis (Lubet
et al., 1989
). Results obtained in rat hepatocytes were then
contrasted with those from in vivo studies.
| |
Materials and Methods |
|---|
|
|
|---|
Materials. Williams' E media, dexamethasone, phenobarbital, phenytoin, and rifampicin were obtained from Sigma. Waymouth 752 media and penicillin G/streptomycin were from GIBCO (Grand Island, NY). Horseradish peroxidase-conjugated goat anti-rabbit antibody was purchased from Amersham. Anti-rat CYP 3A1 and CYP 2B1 antibodies were obtained from Human Biologics (Phoenix, AZ). Collagenase type I was purchased from Worthington (Freehold, NJ). Matrigel, dispase, and type I collagen-coated dishes were purchased from Collaborative (Bedford, MA). All other chemicals were of high purity grade and purchased from commercial sources.
Rat Hepatocyte Isolation and Culture.
Rat hepatocytes were isolated from male Sprague-Dawley rats (weighing
200-250 g) by a two-step collagenase perfusion (Moldeus et
al., 1978
). Only hepatocyte preparations attaining a cell
viability of >85%, as assessed by trypan blue exclusion (0.2% trypan
blue), were used. Hepatocytes were suspended in Williams' E medium
(1 × 106 cells/ml) containing
10-7 M dexamethasone and
10-6 M insulin and were seeded on 60-mm LUX
culture dishes (3 × 106 cells/dish)
previously coated with rat tail type I collagen or Matrigel. Culture
dishes coated with Matrigel were prepared 1 hr prior to cell isolation
by spreading 170 µl of freshly thawed Matrigel (1 mg/ml) in each
plate (Schuetz et al., 1988
). Culture dishes containing
hepatocytes were then placed in a humidified incubator saturated with a
gas mixture of 6% CO2 and 94% air at 37°C.
Cells were allowed 2 hr to attach, at which time the medium was changed
to remove unattached cells. Fresh media were replenished on a daily
basis. The media used for rat hepatocyte cultures were chosen based on
previous studies showing P450 induction by well characterized inducers
(Schuetz et al., 1988
).
Human Hepatocytes Isolation and Culture.
Fresh human liver tissue was obtained from consenting donors undergoing
partial hepatectomies and from unused liver portions from patients
undergoing liver transplants. Tissue samples were transported from the
operating room in ice-cold University of Wisconsin solution. Hepatocyte
isolation was conducted by a two-step collagenase perfusion of the
liver sample as described by Li et al. (1992)
with the
following modifications: the final perfusion buffer contained 650 µg
collagenase/ml, and the tissue (20-30 g) was perfused for
approximately 25 min. Perfusion was via the single blood vessel, which
gave the most blanching of the liver. Rapid perfusate outflow from
large blood vessels on the cut surface of the tissue sample was
minimized by inserting sterile 200-µl pipette tips. This allowed
perfusate to rise up the tip, thereby increasing resistance but not
completely blocking outflow. This modification was found to increase
the yield of viable cells, especially from liver samples that were not
fully encapsulated on all three sides. Cells were then sedimented at
50 g for 2 min and washed three times with ice-cold
phosphate-buffered saline, pH 7.4. Typically, a viability >85% (as
measured by trypan blue exclusion) was obtained. The cells were
suspended (1 × 106 cells/ml) in Waymouth
752/L medium supplemented as previously described (Li et
al., 1992
). The cells were inoculated into 24-well plates (3 × 105 cells/well) coated with rat tail type I
collagen or Matrigel (30 µl/well). Hepatocytes were then treated as
described for rat hepatocytes. The media used for rat hepatocyte
cultures were chosen based on previous studies showing P450 induction
by well characterized inducers (Li et al., 1992
).
Hepatocyte Treatment. Isolated hepatocytes were cultured on collagen or Matrigel-coated dishes. To determine constitutive expression of CYPs 3A and 2B, cells were incubated in culture media and harvested every 24 hr for up to 96 hr, and P450-specific proteins were measured by Western blot immunochemical analysis. To determine the inducibility of P450s, hepatocytes were first allowed 48 hr to adapt to culture conditions followed by exposure to inducers for an additional 48 hr, at which time they were harvested. Inducers were dissolved in dimethyl sulfoxide and added to cultures at a final volume not exceeding 0.25%. The medium was changed 24 hr after treatment, and the cultures were retreated. At 96 hr, hepatocytes were harvested.
Harvesting of Hepatocytes. Hepatocytes cultured on 60-mm dishes were overlaid with ice-cold phosphate-buffered saline containing 5 mM EDTA (4 ml/plate). Cells and gel were then removed with a cell scraper, transferred to 15-ml tubes, and placed on ice for approximately 45 min to solubilize the Matrigel. Cells were resuspended by repeated pipetting until cells separated from the substratum (~10 times) and sedimented by centrifugation at 50g for 2 min. For hepatocytes cultured on 24-well plates, cells were harvested by incubating the cells with 25% dispase (400 µl/well) for approximately 1 hr at 37°C followed by addition of phosphate-buffered saline (1 ml) containing 5 mM EDTA. Cells were then transferred to Eppendorf tubes and sedimented by centrifugation at 50g for 2 min.
Preparation of Samples for Western Blot Analysis.
For rat hepatocytes cultured in 60-mm dishes, the cellular microsomal
fraction was isolated. Briefly, cell pellets were suspended in 100 µl
of ice-cold 0.1 M potassium phosphate, pH 7.4, and homogenized by
sonication. The cell homogenate was centrifuged at 600g for 10 min, followed by ultracentrifugation of the supernatant for 30 min
at 100,000g in a Beckman TL100 tabletop ultracentrifuge. The
microsomal pellet was then resuspended in 0.1 M potassium phosphate, pH
7.4, and stored at
70°C until use.
Western Blot Analysis.
Microsomal protein fraction and cell homogenates (1-10 µg/well) were
resolved on 10% polyacrylamide gels, as described by Laemmli (1970)
.
After electrophoresis, proteins were transferred to nitrocellulose
membranes using the method of Towbin et al. (1979)
. The
blots were incubated with the following antibodies: polyclonal rabbit
anti-rat CYP 3A1 or polyclonal rabbit anti-rat CYP 2B1. Specific
analysis of CYP 3A1 and 2B1 was not possible because the antibody for
CYP 3A1 cross-reacts with 3A2, and the antibody for CYP 2B1
cross-reacts with 2B2 (Parkinson and Gemzik, 1991
). Hence, CYP 3A1 and
2B1 induction will be referred to as CYP 3A1/2 and CYP 2B1/2,
respectively. For human hepatocytes, anti-rat-CYP 3A1 antibody was
found to cross-react with CYP 3A4 to give one band. Proteins were
visualized using ECL (Amersham). ECL detection reagents were used as
per supplier instructions, and the signal generated was analyzed using
a densitometer. P450 induction by drug candidates is expressed by
formulating the densitometry readings as follows:
|
|
|
|
Northern Blot Analysis. Northern blots hybridized with cDNA probes recognizing CYP 3A1 and CYP 2B1 were performed on rat hepatocytes cultured on Matrigel. The cells were incubated with inducers 48 hr after plating and harvested at 2, 4, 6, 8, 16, and 24 hr. Total RNA was extracted from cultured hepatocytes using TRIzol reagent (Life Technologies, Inc.). The RNA (20 µg) was size-fractionated by electrophoresis in 1% agarose formaldehyde gels and transferred to zetaprobe membranes (Bio-Rad). Hybridization was performed using oligonucleotides complementary to rat CYP 3A1 and 2B1, respectively. Oligonucleotides were synthesized on a model 377 Applied Biosystems DNA synthesizer as described by the manufacturer and had the following sequence: CYP 2B1, 5'-GGTTGGTAGCCGGTGTGA-3' and CYP 3A1, 5'-CGGATAGGGCTGTATGAGATTC-3'. Prehybridization solution was 0.25 M sodium phosphate, pH 7.2, 7% sodium dodecyl sulfate, and hybridization was carried out in the same solution with added 32P-kinased oligonucleotide probe (~1 × 106 cpm/ml) at 48°C. Washes were done at 48°C for CYP 3A1 and at 42°C for CYP 2B1 in 20 M sodium phosphate, pH 7.2, 5% sodium dodecyl sulfate. Blots were then stripped and reprobed with a human G3PDH cDNA (Clontech).
In Vivo Treatments.
Sprague-Dawley male rats (four animals/treatment group) were treated po
with 13 drug candidates from our current drug discovery program at 400 mg/(kg × day) for 4 days. The induced CYP 3A1 positive control
group was treated with dexamethasone at 50 mg/(kg × day) for 3 days, whereas the induced CYP 2B1 positive control was treated with a
mixture of phenobarbital/benzafibrate at 50 mg/(kg × day) for 4 days. A negative control group was treated with vehicle only, once a
day for 4 days. At the end of the 4-day study, the animals were
sacrificed and liver microsomes prepared as described by Lu and Levin
(1972)
with the following modifications. Livers were homogenized with 2 volumes of 0.1 M potassium phosphate, pH 7.4. An aliquot of the
homogenate (100 µl) was diluted 10-fold for a total volume
of 1 ml and centrifuged for 10 min at 9000g, and the
supernatant layer then centrifuged for 30 min at 100,000g in
a Beckman TL-100 ultracentrifuge. The resulting microsomal pellet was
resuspended in 200 µl of 0.1 M potassium phosphate, pH 7.4, and
stored at
70°C. P450 analysis was conducted as described above.
| |
Results |
|---|
|
|
|---|
Induction of CYP 3A1/2 and 2B1/2 in Rat Hepatocytes. As shown in fig. 1A, dexamethasone (10 µM) caused a marked increase in CYP 3A1/2 protein in hepatocytes cultured on either matrix. An approximate 50-fold increase was observed in cells cultured on collagen compared with an approximate 10-fold increase in cells on Matrigel. Even though the -fold increase in CYP 3A protein was dependent on the cell matrix, the final protein levels after induction seemed similar. Higher doses of dexamethasone did not further increase CYP 3A1/2 protein accumulation (results not shown). However, as shown in fig. 2, -fold induction of CYP 3A varied from one experiment to another. In these latter experiments, dexamethasone caused a 6.9- to 19.8-fold increase in CYP 3A protein with seven different hepatocyte preparations.
|
|
|
Maintenance of Basal CYP 3A1/2 and 2B1/2 in Rat Hepatocytes. As shown in fig. 4, CYP 3A1/2 protein levels throughout the 4-day period differed between cells cultured on Matrigel from those cultured on collagen. A rapid decrease in CYP 3A1/2 protein was observed during the initial 24 hr in cells cultured on either matrix, followed by recovery to initial levels by 48 hr. Longer incubation periods caused a rapid decrease in CYP 3A1/2 protein levels in hepatocytes cultured on collagen (~30% CYP 3A1/2 protein left after 96 hr compared with day 0). In contrast, CYP 3A1/2 protein levels were better maintained (~80% CYP 3A1/2 left after 96 hr compared with day 0) in hepatocytes cultured on Matrigel. Interestingly, if dexamethasone (100 nM) was omitted from the media, the recovery and maintenance of CYP 3A1/2 protein previously observed did not occur (fig. 4).
|
Induction of CYP 3A1/2 and 2B1/2 In Vitro vs. Induction In Vivo. A series of 13 compounds from our current drug discovery program was used to further validate the in vitro model by directly comparing results obtained in vivo with those from in vitro. Previous experiments in our laboratory with compounds from the same structure class suggested that a 50 µM concentration gave maximal effect (results not shown). Hence, hepatocytes were treated with 50 µM doses. Similarly, in vivo doses of 400 mg/kg were chosen to obtain sufficient drug blood levels to elicit maximum response. Induction of CYP 3A and 2B are defined as a percentage of a classic inducer present in each experiment, rather than -fold increase because of the variability observed between different preparations of hepatocytes. Fig. 5 compares the results obtained from in vivo with those from in vitro experiments. The correlation coefficients (R2) were 0.81 and 0.90 for CYP 3A and 2B, respectively.
|
Induction and Basal Expression of CYP 3A4 in Human Hepatocytes. As found with rat hepatocytes, human hepatocytes cultured on Matrigel retained a rounded morphology, whereas those cultured on collagen rapidly flattened out into monolayers. Addition of 10 µM rifampicin, a well known CYP 3A4 inducer, caused a marked increase in CYP 3A4 immunoreactive protein in cells maintained on Matrigel or collagen (fig. 6). Variability in CYP 3A -fold induction as a result of rifampicin treatment in four different hepatocyte preparations ranged from a 4-35-fold increase (results not shown). Addition of 50 µM phenytoin, another well known CYP 3A4 inducer, also caused induction of CYP 3A4 in cells on Matrigel that was indistinguishable from that of cells on collagen (results not shown).
|
|
Induction of CYP 3A1/2 in Rat vs. CYP 3A4 in Human. As demonstrated in fig. 8A, rifampicin caused a dose-dependent increase in CYP 3A4 induction in human hepatocytes but did not induce CYP 3A1/2 in rat cells (fig. 8B) when cultured on Matrigel. In contrast, dexamethasone was a potent inducer of CYP 3A1/2 in the rat (fig. 8B) but a weak inducer of CYP 3A4 in human hepatocytes (fig. 8A). Furthermore, incubation of human hepatocytes with two drug candidates caused a much higher induction in CYP 3A expression in rat compared with human hepatocytes. Interestingly, when induction of CYP 3A by drug X (50 µM) was calculated as a fold increase, we observed a range from 2- to 8-fold increase in hepatocytes from four different donors. However, when the same induction for drug X was expressed as a percentage of a classic inducer (10 µM rifampicin), the range was from 16 to 34%. On average, maximum -fold induction of CYP 3A1/2 by dexamethasone and CYP 3A4 induction by rifampicin were similar (approximately 10-fold increase).
|
| |
Discussion |
|---|
|
|
|---|
The objective of this study was 2-fold: first, to contrast basal and inducible P450 expression in rat (CYP 3A1 and 2B1) and human (CYP 3A4) hepatocytes cultured on collagen vs. Matrigel; second, to validate the hepatocyte model for P450 induction by directly comparing results obtained in vitro with those from in vivo in the rat.
In this study, we found that basal CYP 3A expression in rat hepatocytes
was affected by the substratum used. Cells cultured on Matrigel were
better able to maintain CYP 3A expression compared with those cultured
on collagen. In contrast, Kocarek et al. (1992)
reported
that CYP 3A mRNA in rat hepatocytes cultured on either Matrigel or
collagen disappears almost completely during the first 2 days in
culture. A possible explanation for this discrepancy may be due to the
difference in media used. In the latter study, the culture media used
were devoid of dexamethasone whereas the media used in this study were
supplemented with 100 nM dexamethasone. We did find that if
dexamethasone was absent from the media, basal CYP 3A expression was
not retained. Other beneficial characteristics reported to be afforded
by low doses of dexamethasone include prevention of cell
dedifferentiation (Sidhu and Omiecinski, 1995
), stimulation of
phenobarbital-mediated induction of CYP 2B1 (Sinclair et
al., 1990
; Waxman et al., 1990
), and maintenance of
cell shape and viability (Castellino et al., 1992
;
Leroux-Nicollet et al., 1983
).
In contrast with maintenance of basal CYP 3A expression, inducibility
of CYP 3A in cells cultured on either collagen or Matrigel was
retained. This confirms previous studies indicating that Matrigel is
not necessary for retaining CYP 3A inducibility by rat hepatocytes in
culture (Schuetz et al., 1988
).
Constitutive expression of CYP 2B in rat hepatocytes was poorly
detected in all the culture conditions studied. This may be due to a
combination of low levels of CYP 2B protein in rat hepatocytes as well
as the limitation of the detection assay. Therefore, culture conditions
best suited for basal CYP 2B expression were not determined. However,
induction of CYP 2B expression in response to phenobarbital was
dependent on the substratum. Induction of CYP 2B expression was
approximately 50-fold in hepatocytes cultured on Matrigel but only
approximately 5-fold in cells cultured on collagen. Previous studies
have reported that hepatocytes cultured on collagen either failed to
respond to phenobarbital or required highly sensitive radiometric
assays to be detected (Bissell and Guzelian, 1980
; Newman et
al., 1982
). Our studies show that even though cells cultured on
Matrigel had a much stronger response, hepatocytes cultured on collagen
did respond to phenobarbital, albeit poorly. More recently, others have
also demonstrated that hepatocytes cultured on collagen can respond to
phenobarbital induction of CYP 2B when a low dose of dexamethasone is
included in the media (Sinclair et al., 1990
; Waxman
et al., 1990
). Interestingly, Kocarek et al.
(1994a)
and Sidhu and Omiecinski (1995)
reported that phenobarbital induction of CYP 2B is markedly enhanced by the presence of a low dose
of dexamethasone (100 nM) but is dramatically down-regulated in the
presence of higher dexamethasone concentrations.
Northern blot analysis showed that accumulation of CYP 3A and 2B
protein in induced rat hepatocytes was preceded by a rise in CYP 3A1
and 2B1 mRNA. Increase in CYP 3A and 2B protein in response to inducers
was first observed 8 hr after inducer was added (results not shown).
This suggested that the induction occurred via transcription. This is
in agreement with in vivo experiments demonstrating that
induction of CYP 3A by dexamethasone required both protein and mRNA
synthesis (Castellino et al., 1992
).
To further validate the use of primary hepatocytes to predict for P450 induction in vivo, a series of compounds varying in their abilities to induce CYP 3A and 2B in rat hepatocytes was also examined in vivo in rats. The treatment doses for both experiments were assumed to cause a maximum response. However, it is possible that some compounds may have not reached sufficiently high blood levels in vivo because of poor bioavailability. Even so, results demonstrated an excellent correlation for CYP 3A and 2B expression obtained in vitro with those from in vivo experiments. These data strongly support the use of primary hepatocytes to predict for CYP 3A and 2B induction in the rat.
In these latter experiments, we defined P450 induction by drug candidates as a percentage of a classic inducer rather than as -fold protein increase. In the case of CYP 3A, defining induction as -fold increase resulted in a high degree of variability between different hepatocyte preparations (fig. 2). This may be due to a number of reasons, including inter-individual variations in basal level of CYP 3A and general state of the cells. Because this assay is not only used to study P450 induction by individual compounds but also to rank order compounds according to their induction potentials, an internal control was deemed necessary to address variability between different hepatocyte preparations. In the case of CYP 2B, basal levels were already at or below the level of detection, hence expressing induction as a -fold increase over basal levels was impossible with our current detection methods. Therefore, induction of CYP 3A and 2B was defined as a percentage of dexamethasone and phenobarbital, respectively.
Ultimately, the reason for using animal models is to provide us with
insight into the possible response in humans. However, differences in
P450 induction between species are known to exist, and therefore rat
hepatocytes may not necessarily be predictive for human. Results from
the rat hepatocyte experiments in this study suggest that hepatocytes
are predictive of P450 induction in vivo, and therefore
human hepatocytes should be predictive for human. Recent studies with
human hepatocytes cultured on collagen have reported that these cells
also retain inducible P450s, including 3A4 (Donato et al.,
1995
; Pichard et al., 1990
). However, to our knowledge,
comparison of induction of CYP 3A4 in human hepatocytes cultured on
collagen vs. Matrigel has not been reported. As clear differences were observed with the rat hepatocyte model, inducibility of CYP 3A4 in human hepatocytes cultured on collagen vs.
Matrigel was investigated. In contrast with rat hepatocytes, basal CYP 3A4 expression in primary cultured human hepatocytes decreased rapidly
in cells cultured on either collagen or Matrigel. Inducibility of 3A4
upon incubation with high doses of rifampicin was also similar in cells
cultured on either matrix. Whereas previous studies have shown
rifampicin to cause induction of CYP 3A4 in human hepatocytes, high
doses of 50 µM are most often used. In this study, a dose of 2 µM
rifampicin was found to elicit a near maximum response. This may be of
particular relevance when induction potentials of drug candidates are
being directly compared with well known inducers like rifampicin.
As reported previously for rat, rifampicin did not cause
induction of CYP 3A in rat hepatocytes (Kocarek et al.,
1994b
; Wrighton et al., 1985
). Interestingly, dexamethasone
was found to be a weak inducer of CYP 3A4 in all of the human cells
obtained to date. Furthermore, induction of CYP 3A in the rat model by
two drug candidates did not translate into similar induction potency of
CYP 3A4 in the human hepatocyte model. Therefore, as previous studies
have shown, CYP 3A induction in the rat may be of questionable relevance to human, and this further stresses the importance of developing in vitro models from human tissue.
Induction potentials of compounds studied in the human hepatocyte
model were also defined as a percentage induction relative to
rifampicin, which was included as a standard inducer in every experiment. This enabled us to compare induction potentials of compounds in cell cultures from different individuals. Our findings are
in agreement with previous reports, which indicate induction of CYP 3A4
expression in human primary hepatocytes shows a large inter-individual
variability (Donato et al., 1995
; Kocarek et al.,
1994b
; Pichard et al., 1990
). For example, Pichard et
al. (1990)
reported CYP 3A4 induction by rifampicin and
dexamethasone to range from 3.7- to 24-fold and from 3.4- to 11.7-fold,
respectively, in a study with human hepatocytes from several donors.
Results from our own study indicated that variability was greatly
minimized by expressing induction as a percentage of a standard
inducer.
In summary, these studies suggest that compared with collagen, Matrigel is a better matrix for the maintenance of basal CYP 3A expression in rat hepatocytes. Also, as previously concluded, CYP 2B induction is markedly greater in hepatocytes cultured on Matrigel than collagen. With human hepatocytes, both basal and inducible CYP 3A4 expression were similar in cells cultured on either matrix. The use of percentage induction relative to a standard inducer is presented as an approach that gives less variable data than -fold induction. This allows for rank ordering of compounds and provides a strategy for circumventing inter-individual variability. This in vitro assay and calculation approach correlated well with in vivo induction. In conclusion, this assay allows for numerous compounds to be evaluated at the drug discovery stage using minimal quantities of drug and markedly fewer animals.
| |
Acknowledgments |
|---|
We acknowledge Dr. Marc Bilodeau from the Hopital Saint-Luc, Montreal, and Dr. Emile Levy from the St. Justine Hospital, Montreal, for providing human liver tissue. The excellent technical assistance from the Laboratory Animal Resource group at Merck Frosst is greatly appreciated.
| |
Footnotes |
|---|
Received June 26, 1997; accepted January 23, 1998.
1 Current address: Astra Research Centre Montreal, 7171 Frederick-Banting, Saint-Laurent, Quebec, Canada.
Send reprint requests to: José M. Silva, Ph.D., Merck Frosst Centre for Therapeutic Research, P.O. Box 1005, Pointe-Claire-Dorval, Quebec H9R 4P8, Canada.
| |
Abbreviations |
|---|
Abbreviations used are: P450, cytochrome P450; G3PDH, glyceraldehyde-3-phosphate dehydrogenase.
| |
References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
D. F. McGinnity, G. Zhang, J. R. Kenny, G. A. Hamilton, S. Otmani, K. R. Stams, S. Haney, P. Brassil, D. M. Stresser, and R. J. Riley Evaluation of Multiple in Vitro Systems for Assessment of CYP3A4 Induction in Drug Discovery: Human Hepatocytes, Pregnane X Receptor Reporter Gene, and Fa2N-4 and HepaRG Cells Drug Metab. Dispos., June 1, 2009; 37(6): 1259 - 1268. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Richert, G. Tuschl, C. Viollon-Abadie, N. Blanchard, A. Bonet, B. Heyd, N. Halkic, E. Wimmer, H. Dolgos, and S. O. Mueller Species Differences in the Response of Liver Drug-Metabolizing Enzymes to (S)-4-O-Tolylsulfanyl-2-(4-trifluormethyl-phenoxy)-butyric Acid (EMD 392949) in Vivo and in Vitro Drug Metab. Dispos., April 1, 2008; 36(4): 702 - 714. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Meneses-Lorente, C. Pattison, C. Guyomard, C. Chesne, R. Heavens, A. P. Watt, and B. Sohal Utility of Long-Term Cultured Human Hepatocytes as an in Vitro Model for Cytochrome P450 Induction Drug Metab. Dispos., February 1, 2007; 35(2): 215 - 220. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Girault, N. Rougier, C. Chesne, R. Lidereau, P. Beaune, I. Bieche, and I. de Waziers SIMULTANEOUS MEASUREMENT OF 23 ISOFORMS FROM THE HUMAN CYTOCHROME P450 FAMILIES 1 TO 3 BY QUANTITATIVE REVERSE TRANSCRIPTASE-POLYMERASE CHAIN REACTION Drug Metab. Dispos., December 1, 2005; 33(12): 1803 - 1810. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Roymans, P. Annaert, J. Van Houdt, A. Weygers, J. Noukens, C. Sensenhauser, J. Silva, C. Van Looveren, J. Hendrickx, G. Mannens, et al. EXPRESSION AND INDUCTION POTENTIAL OF CYTOCHROMES P450 IN HUMAN CRYOPRESERVED HEPATOCYTES Drug Metab. Dispos., July 1, 2005; 33(7): 1004 - 1016. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. R. Gibson, C. Lin, R. Singh, C. M. Brown, K. Richards, J. Brunner, K. Michel, J. Adelsberger, E. Carlini, C. Boothe-Genthe, et al. INDUCTION OF CYP1A IN THE BEAGLE DOG BY AN INHIBITOR OF KINASE INSERT DOMAIN-CONTAINING RECEPTOR: DIFFERENTIAL EFFECTS IN VITRO AND IN VIVO ON MRNA AND FUNCTIONAL ACTIVITY Drug Metab. Dispos., July 1, 2005; 33(7): 1044 - 1051. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. A. Nicoll-Griffith, N. Chauret, R. Houle, S. H. Day, M. D'Antoni, and J. M. Silva USE OF A BENZYLOXY-SUBSTITUTED LACTONE CYCLOOXYGENASE-2 INHIBITOR AS A SELECTIVE FLUORESCENT PROBE FOR CYP3A ACTIVITY IN PRIMARY CULTURED RAT AND HUMAN HEPATOCYTES Drug Metab. Dispos., December 1, 2004; 32(12): 1509 - 1515. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Zhang, A. F. Purchio, K. Chen, J. Wu, L. Lu, R. Coffee, P. R. Contag, and D. B. West A TRANSGENIC MOUSE MODEL WITH A LUCIFERASE REPORTER FOR STUDYING IN VIVO TRANSCRIPTIONAL REGULATION OF THE HUMAN CYP3A4 GENE Drug Metab. Dispos., August 1, 2003; 31(8): 1054 - 1064. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Madan, R. A. Graham, K. M. Carroll, D. R. Mudra, L. A. Burton, L. A. Krueger, A. D. Downey, M. Czerwinski, J. Forster, M. D. Ribadeneira, et al. Effects of Prototypical Microsomal Enzyme Inducers on Cytochrome P450 Expression in Cultured Human Hepatocytes Drug Metab. Dispos., April 1, 2003; 31(4): 421 - 431. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Rae, M. D. Johnson, M. E. Lippman, and D. A. Flockhart Rifampin Is a Selective, Pleiotropic Inducer of Drug Metabolism Genes in Human Hepatocytes: Studies with cDNA and Oligonucleotide Expression Arrays J. Pharmacol. Exp. Ther., December 1, 2001; 299(3): 849 - 857. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. E. Burczynski, M. McMillian, J. B. Parker, S. Bryant, A. Leone, E. R. Grant, J. M. Thorne, Z. Zhong, R. A. Zivin, and M. D. Johnson Cytochrome P450 Induction in Rat Hepatocytes Assessed by Quantitative Real-Time Reverse-Transcription Polymerase Chain Reaction and the RNA Invasive Cleavage Assay Drug Metab. Dispos., September 1, 2001; 29(9): 1243 - 1250. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Yergey, L. A. Trimble, J. Silva, N. Chauret, C. Li, M. Therien, E. Grimm, and D. A. Nicoll-Griffith In Vitro Metabolism of the COX-2 Inhibitor DFU, Including a Novel Glutathione Adduct Rearomatization Drug Metab. Dispos., April 13, 2001; 29(5): 638 - 644. [Abstract] [Full Text] |
||||
![]() |
C. Li, N. Chauret, L. A. Trimble, D. A. Nicoll-Griffith, J. M. Silva, D. MacDonald, H. Perrier, J. A. Yergey, T. Parton, R. P. Alexander, et al. Investigation of the in Vitro Metabolism Profile of a Phosphodiesterase-IV Inhibitor, CDP-840: Leading to Structural Optimization Drug Metab. Dispos., March 1, 2001; 29(3): 232 - 241. [Abstract] [Full Text] |
||||
![]() |
D. A. Nicoll-Griffith, J. M. Silva, N. Chauret, S. Day, Y. Leblanc, P. Roy, J. A. Yergey, R. Dixit, and D. Patrick Application of Rat Hepatocyte Culture to Predict in Vivo Metabolic Auto-Induction: Studies with DFP, a Cyclooxygenase-2 Inhibitor Drug Metab. Dispos., February 1, 2001; 29(2): 159 - 165. [Abstract] [Full Text] |
||||
![]() |
J. T. MacGregor, J. M. Collins, Y. Sugiyama, C. A. Tyson, J. Dean, L. Smith, M. Andersen, R. D. Curren, J. B. Houston, F. F. Kadlubar, et al. In Vitro Human Tissue Models in Risk Assessment: Report of a Consensus-Building Workshop Toxicol. Sci., January 1, 2001; 59(1): 17 - 36. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. P. Bowen, J. E. Carey, A. Miah, H. F. McMurray, P. W. Munday, R. S. James, R. A. Coleman, and A. M. Brown Measurement of Cytochrome P450 Gene Induction in Human Hepatocytes using Quantitative Real-Time Reverse Transcriptase-Polymerase Chain Reaction Drug Metab. Dispos., July 1, 2000; 28(7): 781 - 788. [Abstract] [Full Text] |
||||
![]() |
V. E. Kostrubsky, V. Ramachandran, R. Venkataramanan, K. Dorko, J. E. Esplen, S. Zhang, J. F. Sinclair, S. A. Wrighton, and S. C. Strom The Use of Human Hepatocyte Cultures to Study the Induction of Cytochrome P-450 Drug Metab. Dispos., August 1, 1999; 27(8): 887 - 894. [Abstract] [Full Text] |
||||
![]() |
D. A. Nicoll-Griffith, J.-P. Falgueyret, J. M. Silva, P.-E. Morin, L. Trimble, C.-C. Chan, S. Clas, S. Leger, Z. Wang, J. A. Yergey, et al. Oxidative Bioactivation of the Lactol Prodrug of A Lactone Cyclooxygenase-2 Inhibitor Drug Metab. Dispos., March 1, 1999; 27(3): 403 - 409. [Abstract] [Full Text] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||